Literature DB >> 23294774

Operational challenges and solutions with implementation of an adaptive seamless phase 2/3 study.

Kimberly Spencer1, Kelly Colvin, Brad Braunecker, Marcia Brackman, Joyce Ripley, Paul Hines, Zachary Skrivanek, Brenda Gaydos, Mary Jane Geiger.   

Abstract

A wide variety of operational issues were encountered with the planning and implementation of an adaptive, dose-finding, seamless phase 2/3 trial for a diabetes therapeutic. Compared with a conventional design, significant upfront planning was required, as well as earlier, more integrated cross-functional coordination. The existing infrastructure necessitated greater flexibility to meet the needs of the adaptive design. Rapid data acquisition, analysis, and reporting were essential to support the successful implementation of the adaptive algorithm. Drug supply for nine treatment arms had to be carefully managed across many sites worldwide. Details regarding these key operational challenges and others will be discussed along with resolutions taken to enable successful implementation of this adaptive, seamless trial.
© 2012 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23294774      PMCID: PMC3570869          DOI: 10.1177/193229681200600608

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  2 in total

1.  An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics.

Authors:  Mary Jane Geiger; Zachary Skrivanek; Brenda Gaydos; Jenny Chien; Scott Berry; Donald Berry
Journal:  J Diabetes Sci Technol       Date:  2012-11-01

2.  Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations.

Authors:  Zachary Skrivanek; Scott Berry; Don Berry; Jenny Chien; Mary Jane Geiger; James H Anderson; Brenda Gaydos
Journal:  J Diabetes Sci Technol       Date:  2012-11-01
  2 in total
  6 in total

1.  An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics.

Authors:  Mary Jane Geiger; Zachary Skrivanek; Brenda Gaydos; Jenny Chien; Scott Berry; Donald Berry
Journal:  J Diabetes Sci Technol       Date:  2012-11-01

2.  Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations.

Authors:  Zachary Skrivanek; Scott Berry; Don Berry; Jenny Chien; Mary Jane Geiger; James H Anderson; Brenda Gaydos
Journal:  J Diabetes Sci Technol       Date:  2012-11-01

3.  Adaptive designs in clinical trials: why use them, and how to run and report them.

Authors:  Philip Pallmann; Alun W Bedding; Babak Choodari-Oskooei; Munyaradzi Dimairo; Laura Flight; Lisa V Hampson; Jane Holmes; Adrian P Mander; Lang'o Odondi; Matthew R Sydes; Sofía S Villar; James M S Wason; Christopher J Weir; Graham M Wheeler; Christina Yap; Thomas Jaki
Journal:  BMC Med       Date:  2018-02-28       Impact factor: 8.775

4.  Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

Authors:  Michael Nauck; Ruth S Weinstock; Guillermo E Umpierrez; Bruno Guerci; Zachary Skrivanek; Zvonko Milicevic
Journal:  Diabetes Care       Date:  2014-04-17       Impact factor: 19.112

5.  Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.

Authors:  R S Weinstock; B Guerci; G Umpierrez; M A Nauck; Z Skrivanek; Z Milicevic
Journal:  Diabetes Obes Metab       Date:  2015-05-20       Impact factor: 6.577

6.  Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design.

Authors:  Munyaradzi Dimairo; Elizabeth Coates; Philip Pallmann; Susan Todd; Steven A Julious; Thomas Jaki; James Wason; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Katie Biggs; Jon Nicholl; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMC Med       Date:  2018-11-16       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.